ApconiX enjoyed a double-billing at the recent ‘Predictive Toxicology in Discovery DMPK’ meeting hosted by Sygnature Discovery and Xenogesis in Nottingham. Ruth Roberts kicked off the event with the keynote address entitled ‘Roberts Derisking early drug projects Shortened Version March 2018’ (click the title for pdf). Mike Morton addressed the conference later on in the day with a talk on ‘The Changing Face of Cardiovascular Safety Testing’. There was much discussion with a highly engaged audience on new challenges and successful strategies to identify and progress those projects with the highest probability of success. The key is to generate data early, while we still have choices in target and chemistry!
Share This Story, Choose Your Platform!
About the Author: Ruth Roberts
Professor Ruth A Roberts, PhD, ATS, FBTS, ERT, FRSB, FRCPath. A co-founder of ApconiX, Ruth has 25 years of experience in leading roles in drug safety within large pharma. Ruth is also Chair and Director of Drug Discovery at The University of Birmingham, UK and was previously Global Head of Regulatory Safety at AstraZeneca. With over 140 publications in peer-reviewed journals, she is former president of the British Toxicology Society, former president of EUROTOX, former secretary to SOT and President of the Academy of Toxicological Sciences. Ruth was the recipient of the SOT Achievement award in 2002, the EUROTOX Bo Holmstedt Award in 2009 and the SOT Founders award in 2018 for outstanding leadership in toxicology. Ruth is an established science professional bringing rigorous expert thinking to toxicology, drug discovery and drug development.
